Fulcrum Therapeutics, Inc.

FULC

US3596161097

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
8.25 ^USD	+4.30%		+8.70%	+22.22%

May. 14	Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating	MT
May. 14	Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15	MT

Fulcrum Therapeutics, Inc. Announces Resignation of Bryan Stuart from the Board of Directors

January 04, 2023 at 07:01 am EST

Fulcrum Therapeutics, Inc. announced that Bryan Stuart, is transitioning from the Board of Directors to pursue other opportunities.

Latest news about Fulcrum Therapeutics, Inc.

Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating	May. 14	MT
Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15	May. 14	MT
Trending : Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal	May. 13	DJ
Fulcrum Therapeutics, Sanofi Sign Licensing Deal for Facioscapulohumeral Muscular Dystrophy Treatment	May. 13	MT
Sanofi Signs License Deal for Rare Genetic Muscle Disease Drug	May. 13	MT
Transcript : Fulcrum Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal	May. 13	DJ
Fulcrum Therapeutics, Inc. Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy in The Lancet Neurology	May. 08	CI
Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	Mar. 18	MT
Fulcrum Therapeutics, Inc. Announces Executive Changes	Mar. 18	CI
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index	Mar. 17	CI
GSK: Dr Jeannie Lee joins the Board of Directors	Feb. 29	CF
Piper Sandler Adjusts Price Target on Fulcrum Therapeutics to $15 From $13, Maintains Overweight Rating	Feb. 28	MT
Transcript : Fulcrum Therapeutics, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Goldman Sachs Adjusts Price Target on Fulcrum Therapeutics to $6 From $5, Maintains Neutral Rating	Jan. 25	MT
Transcript : Fulcrum Therapeutics, Inc., Q3 2023 Earnings Call, Nov 07, 2023	Nov. 07
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Spero Therapeutics Appoints Esther Rajavelu Chief Financial Officer	Nov. 01	MT
Fulcrum Therapeutics, Inc. Announces Resignation of Mel Hayes as Chief Operating Officer	23-10-02	CI
Fulcrum Therapeutics Completes Patient Enrollment for Phase 3 Study of Losmapimod	23-09-07	MT
North American Morning Briefing : Nasdaq Futures -2-	23-08-24	DJ
HC Wainwright Upgrades Fulcrum Therapeutics to Buy From Neutral, Adjusts Price Target to $14 From $5	23-08-23	MT

Chart Fulcrum Therapeutics, Inc.

Duration

Period

More charts

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Companyâs clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - H.C. Wainwright BioConnect Investor Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Fulcrum Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.25 USD

Average target price

14.25 USD

Spread / Average Target

+72.73%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FULCRUM THERAPEUTICS, INC.	+22.22%	513M
MODERNA, INC.	+29.77%	49.46B
IQVIA HOLDINGS INC.	+1.00%	42.58B
LONZA GROUP AG	+50.47%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.64B
BIO-TECHNE CORPORATION	+8.22%	13.16B
MEDPACE HOLDINGS, INC.	+32.41%	12.55B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.98B

Other Biotechnology & Medical Research